Nivolumab confers significant OS benefit in recurrent or metastatic head and neck squamous cell carcinoma

Nivolumab (Opdivo, Bristol-Myers Squibb), a PD-1 checkpoint inhibitor, also maintained a favorable safety profile. “Long-term prognosis for patients with metastatic HNSCC has historically been poor,” Robert L. Ferris, MD, director of UPMC Hillman ...

BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma

April 16 (Reuters) - Bristol-Myers Squibb Co: * U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA ...